Results 91 to 100 of about 149 (130)

Circulating Mast Cell Progenitors Are Depleted by Benralizumab in Severe Asthma

Allergy, EarlyView.
Michael Fricker, John Harrington, Sarah A. Hiles, Peter G. Gibson   +3 more
wiley   +1 more source

Meta‐Analysis: Inverse Association Between Helicobacter pylori Infection and Eosinophilic Oesophagitis

Alimentary Pharmacology &Therapeutics, Volume 61, Issue 7, Page 1096-1109, April 2025.
In a large systematic review and meta‐analysis, exposure to Helicobacter pylori was significantly associated with decreased odds (46%) of eosinophilic oesophagitis and oesophageal eosinophilia. ABSTRACT Background Exposure to Helicobacter pylori (H. pylori) has been associated with a decreased risk of eosinophilic oesophagitis (EoE).
Irene Spinelli, Serena Porcari, Chiara Esposito, William Fusco, Francesca Romana Ponziani, Cristiano Caruso, Edoardo Vincenzo Savarino, Antonio Gasbarrini, Giovanni Cammarota, Marcello Maida, Antonio Facciorusso, Gianluca Ianiro   +11 more
wiley   +1 more source

Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A GETAID Multicentre Cohort Study

Alimentary Pharmacology &Therapeutics, Volume 61, Issue 10, Page 1662-1670, May 2025.
In a real‐world cohort of 223 highly refractory Crohn's disease patients, upadacitinib induction resulted in a clinical response in about two‐thirds of patients and in steroid‐free clinical remission in half of the patients, with an acceptable safety profile at week 12. ABSTRACT Background Real‐world effectiveness and safety of upadacitinib in patients
Nicolas Richard, Aurélien Amiot, Philippe Seksik, Romain Altwegg, David Laharie, Lucine Vuitton, Maria Nachury, Guillaume Bouguen, Stéphane Nancey, Cyrielle Gilletta, Cléa Rouilon, Benoît Coffin, Matthieu Allez, Anthony Buisson, Catherine Le Berre, Mathieu Uzzan, Ludovic Caillo, Anne‐Laure Pelletier, Laurent Peyrin‐Biroulet, Mathurin Fumery, GETAID, Marianne Hupé, Vered Abitbol, Mathias Vidon, Felix Goutorbe, Morgane Amil, Hedia Brixi, Alban Benezech, Sandy Kwiatek   +28 more
wiley   +1 more source

Inhibition of phosphodiesterases 1 and 4 prevents myofibroblast transformation in Peyronie's disease

BJU International, Volume 135, Issue 5, Page 810-817, May 2025.
Objectives To investigate which phosphodiesterase (PDE) isoforms are expressed in fibroblasts isolated from the tunica albuginea (TA) of patients with Peyronie's disease (PD), and to measure the potency of PDE inhibitors in preventing transformation of these fibroblasts to profibrotic myofibroblasts.
Sophie L. Harding, Marcus M. Ilg, Stephen A. Bustin, David J. Ralph, Selim Cellek   +4 more
wiley   +1 more source

Anaphylaxis Induced by Goat's and Sheep's Milk: An Allergen That We Should Keep Under Surveillance

Allergy, EarlyView.
Guillaume Pouessel, Elleni‐Sofia Vaia, Catharina Chatain, Valérie Liabeuf, Camille Braun, Anne‐Karine Correard, Elena Bradatan, Pascale Dumond, Yasemin Karaca‐Altintas, Pascale Beaumont, Delphine Delalande, Sélina Tscheiller, Xavier Van der Brempt, Carine Metz‐Favre, Amandine Divaret‐Chauveau, Dominique Sabouraud‐Leclerc   +15 more
wiley   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Efficacy of IDOR‐1117‐2520, a novel, orally available CCR6 antagonist in preclinical models of skin dermatitis

British Journal of Pharmacology, EarlyView.
Background and Purpose The chemokine receptor CCR6 guides pathogenic T17 cells, implicated in autoimmune diseases including psoriasis, to sites of inflammation via the chemokine CCL20. Therefor, pharmacological inhibition of CCR6+ immune cell migration provides a novel therapeutic approach.
Paulina Kulig, Pijus Brazauskas, Madeleine Suffiotti, Emilie Raoult, Ulrike Babilonski, Bérengère Renault, Ursula Grieder, Enrico Vezzali, Peter Blattmann, Marianne M. Martinic, Mark J. Murphy   +10 more
wiley   +1 more source

AI‐Based Objective Severity Assessment of Atopic Dermatitis Using Patient Photos in a Real‐World Setting: A Digital Biomarker Approach

Allergy, EarlyView.
Utako Okata‐Karigane, Masakazu Hirota, Chiaki Takahashi, Akihiro Miyagawa, Ryotaro Ako, Saeko Nakajima, Masaki Futamura, Satoru Yonekura, Yasushi Ogawa, Takenori Inomata, Tetsuo Ishikawa, Yoshihiro Ito, Katsunori Masaki, Sakura Sato, Norito Katoh, Hideaki Morita, Takeya Adachi   +16 more
wiley   +1 more source

JAK–STAT inhibitory effect of IN‐115314, a novel small molecule inhibitor, and pharmacokinetic/pharmacodynamic study in canine

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose The JAK–STAT signalling pathway has been extensively spotlighted as a therapeutic target for various diseases. This study assessed the inhibitory effects of a novel small molecule, IN‐115314, on JAK–STAT pathway. Experimental Approach The IC50 values of IN‐115314 for JAK1–pSTAT3 and JAK2–pSTAT5 were determined in canine ...
Jae‐Hun Ahn, Joohwan Kim, Jina Kwak, Jooil Kim, Na‐Young Lee, Heejin Choi, Hee‐Jin Bae, So‐Hyun Cho, Sung‐Gu Jung, Hye‐Mi Kwon, Euna Kwon, Donghyun Kim, Myeongjoong Kim, Daseul Yoon, Seohyun Kim, Bongtae Kim, Byeong‐Cheol Kang   +16 more
wiley   +1 more source

Patients With Atopic Dermatitis Show Increased Clonal Hematopoiesis and Risk of Hematological Cancer

Allergy, EarlyView.
Verena Vogi, Emina Jukic, Robert Gruber, Andre Fiona, Deborah Minzaghi, Johannes Zschocke, Sandrine Dubrac   +6 more
wiley   +1 more source